These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 34341531)
1. Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids. Chen KG; Park K; Spence JR Nat Cell Biol; 2021 Aug; 23(8):822-833. PubMed ID: 34341531 [TBL] [Abstract][Full Text] [Related]
2. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis. Martin P; Clarke C EBioMedicine; 2021 Sep; 71():103567. PubMed ID: 34454401 [No Abstract] [Full Text] [Related]
3. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lim SH; Campbell N; Johnson M; Joseph-Pietras D; Collins GP; O'Callaghan A; Fox CP; Ahearne M; Johnson PWM; Goldblatt D; Davies AJ Lancet Haematol; 2021 Aug; 8(8):e542-e544. PubMed ID: 34224667 [No Abstract] [Full Text] [Related]
4. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844 [TBL] [Abstract][Full Text] [Related]
5. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM Front Immunol; 2021; 12():658519. PubMed ID: 34276652 [TBL] [Abstract][Full Text] [Related]
6. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine. Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239 [No Abstract] [Full Text] [Related]
7. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. Iqbal Yatoo M; Hamid Z; Parray OR; Wani AH; Ul Haq A; Saxena A; Patel SK; Pathak M; Tiwari R; Malik YS; Sah R; Rabaan AA; Rodriguez Morales AJ; Dhama K Hum Vaccin Immunother; 2020 Dec; 16(12):2891-2904. PubMed ID: 32703064 [TBL] [Abstract][Full Text] [Related]
9. Vaccine against SARS-CoV-2 in previously infected health care workers. Parisi SG EBioMedicine; 2021 Sep; 71():103556. PubMed ID: 34454402 [No Abstract] [Full Text] [Related]
10. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. Edara VV; Pinsky BA; Suthar MS; Lai L; Davis-Gardner ME; Floyd K; Flowers MW; Wrammert J; Hussaini L; Ciric CR; Bechnak S; Stephens K; Graham BS; Bayat Mokhtari E; Mudvari P; Boritz E; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Douek DC; Sahoo MK; Sibai M; Solis D; Webby RJ; Jeevan T; Fabrizio TP N Engl J Med; 2021 Aug; 385(7):664-666. PubMed ID: 34233096 [No Abstract] [Full Text] [Related]
11. Audio Interview: Assessing the Effect of Vaccination and Prior SARS-CoV-2 Infection. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2022 Oct; 387(17):e50. PubMed ID: 36300981 [No Abstract] [Full Text] [Related]
12. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867 [No Abstract] [Full Text] [Related]
13. Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. Figueroa JP; Hotez PJ; Batista C; Ben Amor Y; Ergonul O; Gilbert S; Gursel M; Hassanain M; Kang G; Kaslow DC; Kim JH; Lall B; Larson H; Naniche D; Sheahan T; Shoham S; Wilder-Smith A; Sow SO; Strub-Wourgaft N; Yadav P; Bottazzi ME PLoS Med; 2021 Sep; 18(9):e1003772. PubMed ID: 34516558 [TBL] [Abstract][Full Text] [Related]
14. Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. McDade TW; Demonbreun AR; Sancilio A; Mustanski B; D'Aquila RT; McNally EM Sci Rep; 2021 Aug; 11(1):17325. PubMed ID: 34462501 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
16. The long road. Cohen J Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838 [No Abstract] [Full Text] [Related]
19. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. Shah P; Canziani GA; Carter EP; Chaiken I Front Immunol; 2021; 12():637651. PubMed ID: 33767706 [TBL] [Abstract][Full Text] [Related]
20. [Immune memory against SARS-CoV-2: Antibodies against the initial infection and memory B cells for the future ones]. Reynaud CA; Weill JC; Chappert P; Mahévas M Med Sci (Paris); 2021; 37(8-9):722-725. PubMed ID: 34346865 [No Abstract] [Full Text] [Related] [Next] [New Search]